Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
PORTAGE, Mich. - Inari Medical, now part of Stryker (NYSE:SYK), announced Tuesday the launch of its next-generation InThrill Thrombectomy System, designed for small vessel and arteriovenous (AV) access thrombectomy procedures. Stryker, a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $153 billion and robust revenue growth of nearly 11% over the last twelve months, continues to expand its medical technology portfolio.
The new 8 French over-the-wire system consists of the InThrill thrombectomy catheter and InThrill sheath. According to the company, the device features increased radial force for improved wall apposition, an offset single open mouth for optimized clot capture, internal struts for even clot distribution, and a redesigned backend for improved ergonomics.
The first commercial procedure using the new system was performed on May 19 by Dr. Joshua Pinter and Dr. Anish Ghodadra at UPMC health care system. "The next generation of InThrill has made our thrombectomies more effective and consistent than ever," said Dr. Pinter in the press release.
Tim Lanier, president of the Inari Division, stated, "This latest innovation delivers new tools and enriches our work with physicians in the vascular space."
The InThrill Thrombectomy System is indicated for non-surgical removal of thrombi and emboli from blood vessels, including dialysis access sites, as well as for injection, infusion, and aspiration of contrast media and other fluids into or from blood vessels. The system is intended for use in peripheral vasculature but not for deep vein thrombosis treatment.
Stryker acquired Inari Medical on February 19, 2025, as part of its expansion in medical device technologies.
In other recent news, Stryker Corporation announced it received FDA 510(k) clearance for its Incompass Total Ankle System, which is designed for patients with severely damaged ankle joints. This new system integrates technologies from Stryker’s existing platforms to enhance surgical flexibility and long-term fixation. Additionally, Moody’s Ratings upgraded Stryker’s senior unsecured notes to A3, citing strong growth prospects and robust free cash flow to support research and development. Barclays maintained its Overweight rating on Stryker, highlighting the sustained success of the company’s MedSurg and NeuroTech division, which has shown a 10.4% compound average growth rate over 12 years. Stryker also received FDA clearance for its OptaBlate basivertebral nerve ablation system, aimed at relieving chronic vertebrogenic low back pain. This minimally invasive system targets the basivertebral nerve, providing a new option for patients who have not found relief from other treatments. Lastly, Stryker shareholders approved amendments to several incentive plans, increasing the number of shares available and extending the plans’ duration. These developments reflect Stryker’s ongoing efforts to innovate and expand its product offerings while maintaining strong financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.